RxDoctor Payments Data

Colleen Maturana, MD

Ophthalmology · New York, NYNPI 1174905202

Payments from drug & device makers

$3,973in general payments, 2019–2025

Across 118 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$822
  • AbbVie$641
  • Alcon$572
  • NEW World Medical,inc.$423
  • Bausch & Lomb Americas Inc.$399
  • Harrow Eye, LLC$177
  • plus $940 from 11 others

What the payments were for

  • Food & beverage$3,973100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,973 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$453,745
Medicare patients
943
Services billed
3,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost142$68,410
LumiganBimatoprost64$38,878
RestasisCyclosporine27$35,162
RhopressaNetarsudil Mesylate62$20,915
MieboPerfluorohexyloctane/Pf14$10,193
Alphagan PBrimonidine Tartrate17$10,093
VyzultaLatanoprostene Bunod17$9,937
CombiganBrimonidine Tartrate/Timolol27$8,456
Prednisolone Acetate150$8,095
Cyclosporine15$7,736
Brimonidine Tartrate115$6,681
SimbrinzaBrinzolamide/Brimonidine Tart30$6,128
ProlensaBromfenac Sodium17$5,888
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$5,605
Timolol Maleate127$4,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$641$92,590135 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$125$89,326204 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$399$20,12931 claims
AlconSimbrinza$572$6,12830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →